Nkarta (NKTX) vs Yarrow Bioscience (YARW)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Yarrow Bioscience (YARW) has outperformed Nkarta (NKTX) over the past year, losing 4.6% versus a loss of 4.7%. Over five years, NKTX leads with a -87.7% price change compared with -98.2% for YARW. Yarrow Bioscience is the larger company by market cap ($183.4 million vs $161.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NKTX | YARW |
|---|---|---|
| Share price | $2.25 | $19.71 |
| Market cap | $161.16M | $183.39M |
| 1-day change | +1.35% | -0.81% |
| YTD return | +21.62% | -32.03% |
| 1-year return | -4.66% | -4.55% |
| 5-year return | -87.73% | -98.20% |
| EPS (TTM) | $-1.58 | — |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.72 | $46.95 |
| 52-week low | $1.70 | $16.05 |
| Distance from 52-week high | -39.52% | -58.02% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +381.33% | +189.19% |
| Average volume | 602.17K | 85.28K |
| Shares outstanding | 71.62M | 9.30M |
| Employees | 106 | 7 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Nkarta
NKTX stock →Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis.
Healthcare · Biotechnology · 106 employees
About Yarrow Bioscience
YARW stock →Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases.
Healthcare · Biotechnology · 7 employees
NKTX vs YARW FAQ
Which is bigger, Nkarta or Yarrow Bioscience?
Yarrow Bioscience (YARW) is larger, with a market capitalization of $183.39M compared with $161.16M for Nkarta (NKTX).
Which stock has performed better over the past year, NKTX or YARW?
YARW returned -4.55% over the past 12 months, compared with -4.66% for NKTX (price return, excluding dividends). Past performance does not predict future results.
Are Nkarta and Yarrow Bioscience in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.